ERBB3 and non-small cell lung carcinoma: Specifically, when EGFR-mutated NSCLC cells have coexisting MET genomic amplification, these cells could maintain the antiapoptotic HER3/PI3K/AKT signaling, even under EGFR-TKI treatment [27] through HER3 coupling with MET instead of HER3/EGFR coupling to maintain HER3 activation.